RenBio

MYO™ TECHNOLOGY

Make Your Own Technology

An exciting, innovative delivery platform for Antibodies and Therapeutic Proteins

February 26, 2024

Forward-looking statements

No representation, express or implied, is being given by RenBio, Inc. or its affiliates (individually and collectively, the "Company") as to the accuracy or completeness of the information contained herein. The Company expressly disclaims any and all liability (whether known or unknown, asserted or unasserted, absolute or contingent, accrued or unaccrued, liquidated or unliquidated, due or become due, or otherwise) or any indemnification or other obligation which may be based on this presentation, errors therein or omissions therefrom.

This presentation is not and shall not be construed or viewed in any way to be a commitment, offer, obligation or agreement with respect to any transaction with the Company.

This presentation may contain "forward-looking" statements, which involve risks, uncertainties, and assumptions. All statements, other than statements of historical fact, should be deemed forward-looking statements, and reflect the current expectations and assumptions about future events and are not guarantees of future performance. Actual results could differ materially from the current expectations because of many factors. All forward-looking statements herein reflect opinions only as of the date of this presentation.

Executive Summary

Potential paradigm shift in delivery of antibodies and therapeutic proteins for treatment of chronic diseases and prevention of infectious diseases.

MYO TECHNOLOGY

Intramuscular electroporation of plasmid DNA enables durable, in vivo production of antibodies and therapeutic proteins

Company and financing overview

$4M Series Seed
$24M Series A
$13M Nondilutive grants
Located in New York City
13 Employees

- ✓ **Patent-protected platform technology**
- ✓ **Substantial commercial potential identified across a variety of indications**
- ✓ **Established clear proof of concept**
- ✓ **Able to support a wide variety of payloads**
- ✓ **Solves supply and distribution challenges associated with biologics**
- ✓ **Early clinical development funded by government agencies in Zika prevention**

Rachel A. Liberatore, PhD
President & Chief Scientific Officer

BA in Molecular Biology from Princeton University | PhD in Cellular & Molecular Biology from Columbia University | 10+ years in scientific leadership and team management

Yaoxing Huang, PhD
Co-founder and Scientific Advisor

Associate Professor, Columbia University

David D. Ho, MD
Co-founder and Scientific Advisor

Professor, Columbia University & Director, Aaron Diamond AIDS Research Center | Scientific Founder, TaiMed Biologics (US FDA approved Trogarzo®) | Time Man of the Year

Our story

Considered, steady progress built on a solid foundation to advance the delivery of first-in-class and best-in-class DNA therapeutic technologies to humans



There remain high levels of unmet need for the optimal development, supply, and use of antibodies and therapeutic proteins today

A faster, smoother, and cost-effective delivery platform would address many of these needs

Challenges that remain

Therapies with **short half-lives** require **frequent dosing** and ongoing monitoring, leading to inefficient clinic workflows and a risk of suboptimal efficacy and tolerability

Meeting the need

Improving clinical utility for healthcare professionals by significantly reducing clinical workload with **easier, less frequent dosing**, negating the need for regular infusion clinics, reducing the burden of patient monitoring, and guaranteeing **real world efficacy** that meets that seen in clinical trials as patient adherence is no longer part of the equation

Specialized production, purification and cold-chain requirements for transport and storage, drive long production lead times, complicate supply and distribution, and result in an unnecessarily **high COGs**

Reducing the COGs and ensuring flexible, fast product supply, distribution and storage by **simplifying manufacturing processes**, negating the need for specialized production facilities and removing any onerous **distribution and storage** criteria

RenBio

Our MYO Technology™ delivery platform enables an individual to make their own antibodies and therapeutic proteins, improving on frequent dosing regimens required by conventional delivery of recombinant proteins

MYO™ TECHNOLOGY

Bio Blueprints
Proprietary DNA plasmid encoding antibody or protein therapeutic

Delivery Device
Proprietary electroporation device

Antibody Factory
An individual's muscle cells, produce antibodies or therapeutic proteins following in vivo electroporation

Antibodies/Therapeutic Proteins
Circulate systemically following secretion by muscle cells

We continue to build the evidence to demonstrate the high value of our technology platform

In vivo animal data demonstrates promise for durable delivery of a payload within the therapeutic window





RenBio

Unpublished, internal data

Our MYO Technology™ has compelling advantages compared to other novel delivery platforms when applied to the management of systemic, chronic disease and prevention of infectious disease

Feature	MYO™ Technology	mRNA	AAV Gene Therapy
Durability	Months to years	Weeks to months	Years/Permanent
Redosable	****	***	*
Large genetic payload	****	***	**
Large scale manufacturing	****	**	*
Freedom from cold chain	****	*	*
Clinical safety of technology	***	***	*
Opportunity	Systemic activity Chronic disease Tx, Infectious disease Px	Localized activity Short half-life Vaccines	Specific tissue target Genetic disease Tx

RenBio

MYO Technology™ has the potential for broad applicability

Compelling in vivo animal efficacy studies, using well accepted models, show applicability for diverse range of diseases from oncology to autoimmune

Arthritis



Breast Cancer



Influenza



Anemia



RenBio

Unpublished, internal data

Targeting high value, high growth markets

The market for antibodies and therapeutic proteins is very large with wide utility.

Growing rapidly, the global market for antibodies was valued at $210B in 2022, with an expected CAGR of 11.04% from 2023 to 2030.



* Source = Grand View Research Report ID: GVR-1-68038-280-8 https://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market

Clinical proof-of-concept with a monoclonal antibody (Zika) and a therapeutic protein (G-CSF) will support expansion into multiple, high value markets

Phase 1 data with prototype molecules (anti-Zika monoclonal antibody and G-CSF) will demonstrate the potential for the MYO Technology platform



RenBio

Proof of concept data for G-CSF and anti-IL-23 delivery with MYO Technology

Animal models of neutropenia and plaque psoriasis demonstrate the potential for MYO Technology in these indications

MYO G-CSF: DNA dose-dependent treatment of anti-Ly6G-induced neutropenia



MYO anti-IL-23: DNA-based delivery of guselkumab potently inhibits IL-23-induced psoriasis



RenBio

Unpublished, internal data

Proof of concept data for GLP-1 delivery with MYO Technology

DNA-based delivery of a GLP-1 receptor agonist results in sustained expression and promotes weight loss and and suppresses weight gain in an animal model of diet-induced obesity







Unpublished, internal data

Three pillars of opportunity identified for our MYO Technology™ platform

Multiple opportunities exist for biopharma partners to realize the full potential of drugs in large and rapidly growing markets

A track record of accomplishment, planning for future success

Significant milestones achieved following each funding round

MYO™ TECHNOLOGY

Seed ($4M) to Series A

- PK and Efficacy demonstrated in small animal models
- Technology scale up demonstrated in large animal models
- Additional non-dilutive funding secured ($3.4M DARPA, $1.75M Bill & Melinda Gates Foundation)

Series A ($24M) to present

- MYO Technology device and plasmid design locked
- 2 patent applications filed (device, plasmid)
- Manufacturing of GLP and clinical devices initiated
- First GMP plasmid manufacturing campaign initiated
- FDA feedback on Pre-IND questions and briefing package received
- NHP studies initiated
- Further non-dilutive funding secured ($2M New York State Biodefense Commercialization Fund, $3.2M DARPA, $2.9M Wellcome Trust)

Planned for Series B ($27M)

- Completion of IND-enabling studies and Phase 1 clinical study for lead clinical development program (*fully funded with non-dilutive funds*)
- IND-enabling activities and Phase 1 clinical study for first internally funded clinical development program
- Proof-of-concept animal studies for second and third planned internal clinical development programs
- Biopharma partnerships
- Board of Directors enhancement for next phase of growth

Clinical and Business Development Team Partners

- Martin Markowitz, MD – Clinical
  - Clinical Director and Principal Investigator on ~80 clinical trials
- Jim Ackland – Regulatory, preclinical
  - >45 years experience in development and regulatory affairs for biopharmaceutials
- Meredith Brown-Tuttle, FRAPS – Regulatory, biologics
  - >31 years experience in regulatory affairs for biologics
- Sheila Ramerman, RAC-US, RAC-Devices – Regulatory, medical devices
  - >30 years experience in electromedical devices
- Joanne Kelley, LLB – Business Development
  - Former Vice President of Business Development, Head of Transactions at AstraZeneca
- Jill Ogden, PhD – Business Development
  - >30 years commercial/transactional expertise in biopharmaceutical industry

Thank you

Help us to transform the lives of people globally
via the delivery of therapeutic antibodies and proteins enabled by our MYO Technology™, easing and expanding the use of these therapeutics.

Contact: **Rachel A. Liberatore, PhD**
President & Chief Scientific Officer
rachel.liberatore@renbio.com
www.renbio.com

RenBio